Clinical Trial DRUG CX-839-003
- A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients with Relapsed and/or Treatment-Refractory Leukemia
- Principal Investigator
- Olga Frankfurt
- Status: Accepting New Patients
- Study Type: Therapeutic, Treatment
- Protocol No:.DRUG CX-839-003
- The purpose of this study is to evaluate the safety of an investigational drug, CB-839, and to determine the best dose to use for future studies.
- Leukemia (blood cell cancer) begins in the bone marrow, which is a blood-forming tissue, and causes the abnormal growth of blood cells. Leukemia may become active after having previously responded to treatment (relapsed) and/or does not respond to standard treatment (refractory). When this happens there are limited treatment options. The medical and scientific communities are always exploring new ways to treat these cancers. CB-839 is an investigational drug, which means it has not been approved by the United States Food and Drug Administration (FDA) for use outside of clinical studies. This trial will evaluate how well this drug works on relapsed and/or refractory leukemia and study the side effects to decide the highest dose that can be given safely.
Some of the eligibility criteria include:
- Participants must be 18 years of age or older.
- Participants must have relapsed or refractory leukemia.
- Participants with acute promyelocytic leukemia (APL) are not included in this study.
- Description of Treatment
- There are 2 parts to this study. Part 1 is called Dose Escalation. Part 2 is called Dose Expansion. CB-839 is taken orally (by mouth). The study doctor will tell participants what part they will be in and let them know the dosage of CB-839 they will receive. The amount of drug that will be given may vary. The dose is based on when a participant starts the study and what side effects, good and/or bad, have been seen.
- Sara Duffey
Clinical Research and Education Specialist
Robert H. Lurie Comprehensive Cancer Center
Find Related Clinical Trials
Browse by Disease Sites
Other Clinical Trials by Olga Frankfurt
- CALGB 10701: A Phase II Study of Dasatinib (Sprycel®) (Ind #73969, Nsc #732517) as Primary Therapy Followed by Transplantation for Adults = 18 Years with Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia by CALGB, ECOG and SWOG
- An Open-label, Randomized Phase 3 Study of Inotuzumab Ozogamicin Compared to a Defined Investigator’s Choice in Adult Patients with Relapsed or Refractory CD22-Positive Acute Lymphoblastic Leukemia (ALL)
- Phase III, Multicenter, Randomized, Trial Of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients 60-75 Years Of Age with Untreated High Risk (Secondary) AML
- A Phase 1/2 Study of CNDO-109-Activated Allogeneic Natural Killer Cells in Patients with High Risk Acute Myeloid Leukemia in First Complete Remission (CR1)
- An Open Label, Multi-Center Imatinib Roll-Over Protocol for Patients who Have Completed a Previous Novartis sponsored Imatinib Study and are Judged by the Investigator to Benefit from Continued Imatinib Treatment
- A Randomized, Open Label, Phase 2 Study of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) Versus Specified Physician’s Choice in Patients = 60 Years Old with Relapsed/Refractory Acute Myeloid Leukemia (AML) Who are Ineligible for Intensive Chemotherapy and/or Transplantation
last updated: 20-Oct-14 07:30 PM
Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.